We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)- Horizon Discovery Group plc

4 May 2018 10:03

RNS Number : 1635N
JPMorgan Securities Plc
04 May 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Horizon Discovery Group plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Corporate Broker and Financial Advisor to Abcam plc

(d) Date dealing undertaken:

03 May 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes, Abcam plc

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received (GBP)

 

Lowest price per unit paid/received (GBP)

 

Ordinary Shares

Purchases

 

Sales

100,398

 

79,809

1.9600

 

1.9450

1.8801

 

1.9000

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(GBP)

Ordinary Shares

Equity Swaps

 

Long

 

Short

77,829

 

218

 6,016

 65,144

 7,874

 4,437

 10,390

 4,339

1.9000

 

1.8801

1.9000

1.9077

1.9214

1.9272

1.9337

1.9578

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBP)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit (GBP)

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit (GBP)

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

(GBP)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

04 May 2018

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERFKQDKCBKKKPK
Date   Source Headline
18th Apr 20167:00 amRNSChange of Adviser
7th Apr 20167:00 amRNSNotice of Results
24th Mar 201612:29 pmRNSAdditional Listing
24th Mar 20168:54 amRNSAdditional Listing
15th Mar 20167:00 amRNSHorizon Discovery hosts symposium on gene editing
2nd Mar 20167:00 amRNSHorizon Discovery Group forms Immuno-oncology JV
26th Jan 20164:04 pmRNSHolding(s) in Company
22nd Jan 20161:21 pmRNSHolding(s) in Company
18th Jan 20167:00 amRNSTrading Update
15th Jan 20164:14 pmRNSAdditional Listing
12th Jan 201610:09 amRNSAdditional Listing
17th Dec 20159:52 amRNSDirector/PDMR Shareholding
11th Dec 20159:23 amRNSAdditional Listing
25th Nov 20157:00 amRNSThree diagnostic agreements worth an initial $3.3m
13th Nov 20157:00 amRNSDirector Dealings
12th Nov 20151:30 pmRNSBoard Change
12th Nov 20157:00 amRNSHolding(s) in Company
12th Nov 20157:00 amRNSHolding(s) in Company
6th Nov 20153:51 pmRNSDirector/PDMR Shareholding
29th Oct 20157:00 amRNSTotal Voting Rights
28th Oct 20157:00 amRNSNew E-Commerce Platform and UK Headquarters
21st Oct 20158:48 amRNSAdditional Listing
15th Oct 20155:44 pmRNSGrant of options under Long Term Incentive Plan
7th Oct 20154:00 pmRNSIssue of Equity
7th Oct 20157:00 amRNSIn-licensing agreement with Servier
22nd Sep 20157:00 amRNSHalf Yearly Report
18th Sep 201510:17 amRNSAdditional Listing
16th Sep 20157:00 amRNSCell Line Licensing Agreement with LakePharma Inc
9th Sep 20157:00 amRNSHZD & Abcam plc Sign License & Supply Agreement
3rd Sep 20157:00 amRNSCancer Research Collaboration with Redx Pharma
3rd Sep 20157:00 amRNSCancer Research Collaboration
1st Sep 201511:49 amRNSAdditional Listing
1st Sep 20157:04 amRNSNotice of Interim Results
27th Jul 20157:00 amRNSHZD To Invest c£10M In Cancer R&D
20th Jul 20157:00 amRNSTrading update
17th Jul 201512:34 pmRNSAdditional Listing
19th Jun 201511:28 amRNSResult of AGM
26th May 20154:46 pmRNS2014 Annual Report and Accounts & AGM Notification
22nd May 20153:28 pmRNSHolding(s) in Company
21st May 20156:04 pmRNSHolding(s) in Company
18th May 201511:50 amRNSResult of General Meeting and Issue of Equity
14th May 20157:00 amRNSDirectorate Change
5th May 20157:01 amRNSCorrection to Results of Placing
1st May 20154:15 pmRNSResults of Placing
1st May 201511:08 amRNSProposed placing and Notice of General Meeting
23rd Apr 20157:00 amRNSHORIZON AND TRANSGENOMIC SIGN OEM AGREEMENT
20th Apr 20157:00 amRNSHorizon & Thermo Fisher Scientific Sign Agreement
14th Apr 20157:07 amRNSPreliminary Results
10th Apr 20153:30 pmRNSAdditional Listing
27th Mar 20158:29 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.